|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 June 2013 |
|
Main ID: |
NCT00895037 |
|
Date of registration:
|
01/05/2009 |
|
Primary sponsor: |
|
|
Public title:
|
Study Evaluating Pharmacovigilance Of Refacto AF
|
|
Scientific title:
|
Pharmacovigilance Evaluation Of Refacto AF In Germany And Austria |
|
Date of first enrolment:
|
November 2009 |
|
Target sample size:
|
180 |
|
Recruitment status: |
Recruiting |
|
URL:
|
http://clinicaltrials.gov/show/NCT00895037 |
|
Study type:
|
Observational |
|
Study design:
|
Observational Model: Cohort, Time Perspective: Prospective
|
|
|
Countries of recruitment
|
|
Austria
|
Germany
| | | | | | |
|
Contacts
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
1-800-718-1021 |
|
Email:
|
|
|
Affiliation:
|
|
|
|
Name:
|
Pfizer CT.gov Call Center |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Pfizer |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Patients with hemophilia A of any severity already receiving or starting treatment
with ReFacto AF
Exclusion Criteria:
- Patients with Hemophilia A treated with a product other than Refacto AF
Age minimum:
N/A
Age maximum:
N/A
Gender:
Male
|
|
Health Condition(s) or Problem(s) studied
|
|
Hemophilia A
|
|
Intervention(s)
|
|
Drug: ReFacto AF (Moroctocog alfa)
|
|
Primary Outcome(s)
|
|
Reporting of adverse events
[Time Frame: 36 months]
|
|
Secondary Outcome(s)
|
|
Efficacy in controlling bleeding
[Time Frame: 36 months]
|
|
Secondary ID(s)
|
|
3082B2-4420
|
|
B1831016
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|